Tumor vaccines in 2010: need for integration

Cell Immunol. 2010;263(2):138-47. doi: 10.1016/j.cellimm.2010.03.019. Epub 2010 Apr 3.

Abstract

Induction of tumor-specific immunity is an attractive approach to cancer therapy, however to date every major pivotal trial has resulted in failure. While the phenomena of tumor-mediated immune suppression has been known for decades, only recently have specific molecular pathways been elucidated, and for the first time, rationale means of intervening and observing results of intervention have been developed. In this review we describe major advances in our understanding of tumor escape from immunological pressure and provide some possible therapeutic scenarios for enhancement of efficacy in future cancer vaccine trials.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm*
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use*
  • Dendritic Cells / immunology
  • Humans
  • Immune Tolerance / immunology
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Oxidative Stress
  • T-Lymphocytes / immunology

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines